Document Classification

Section Type: RESULTS

Text: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept : in the ERASURE study, the rates were 81. 6 % with 300 mg of secukinumab, 71. 6 % with 150 mg of secukinumab, and 4. 5 % with placebo ; in the FIXTURE study, the rates were 77. 1 % with 300 mg of secukinumab, 67. 0 % with 150 mg of secukinumab, 44. 0 % with etanercept, and 4. 9 % with placebo (P < 0. 001 for each secukinumab dose vs. comparators).